These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38833542)

  • 1. Improving preparedness for introducing and scaling up long-acting HIV pre-exposure prophylaxis in Asia.
    Bavinton BR; Schmidt HA; Mills S; Phanuphak N
    Sex Health; 2024 Jun; 21():. PubMed ID: 38833542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Men Who Have Sex with Men in Guangxi, China.
    Liu L; Ruan Y; Chen S; Tang H; Liu J; Jiang Y; Pei H; Huang T; Lan G; Xie Y
    Arch Sex Behav; 2024 Jul; 53(7):2795-2806. PubMed ID: 38849704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting injectable cabotegravir for the prevention of HIV infection.
    Clement ME; Kofron R; Landovitz RJ
    Curr Opin HIV AIDS; 2020 Jan; 15(1):19-26. PubMed ID: 31644481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study.
    Smith JA; Garnett GP; Hallett TB
    J Infect Dis; 2021 Oct; 224(7):1179-1186. PubMed ID: 32492704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
    Brogan AJ; Davis AE; Mellott CE; Fraysse J; Metzner AA; Oglesby AK
    Pharmacoeconomics; 2024 Apr; 42(4):447-461. PubMed ID: 38267806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Marzinke MA; Grinsztejn B; Fogel JM; Piwowar-Manning E; Li M; Weng L; McCauley M; Cummings V; Ahmed S; Haines CD; Bushman LR; Petropoulos C; Persaud D; Adeyeye A; Kofron R; Rinehart A; St Clair M; Rooney JF; Pryluka D; Coelho L; Gaur A; Middelkoop K; Phanuphak N; Cohen MS; Hendrix CW; Anderson P; Hanscom B; Donnell D; Landovitz RJ; Eshleman SH
    J Infect Dis; 2021 Nov; 224(9):1581-1592. PubMed ID: 33740057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?
    Liegeon G; Ghosn J
    HIV Med; 2023 Jun; 24(6):653-663. PubMed ID: 36468218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.
    Grinsztejn B; Torres TS; Hoagland B; Jalil EM; Moreira RI; O'Malley G; Shade SB; Benedetti MR; Moreira J; Simpson K; Pimenta MC; Veloso VG;
    JMIR Public Health Surveill; 2023 Apr; 9():e44961. PubMed ID: 37074775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition.
    Fonner VA; Ridgeway K; van der Straten A; Lorenzetti L; Dinh N; Rodolph M; Schaefer R; Schmidt HA; Nguyen VTT; Radebe M; Peralta H; Baggaley R
    AIDS; 2023 May; 37(6):957-966. PubMed ID: 36723489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.
    Bares SH; Scarsi KK
    Curr Opin HIV AIDS; 2022 Jan; 17(1):22-31. PubMed ID: 34871188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC).
    Warren M; Nyagah W; Verde Hashim C; Rodolph M; Schaefer R; Schmidt HA; Baggaley R
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26094. PubMed ID: 37439050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.
    Raccagni AR; Galli L; Lucente MF; Candela C; Lolatto R; Trentacapilli B; Ponta G; Messina E; Gianotti N; Castagna A; Nozza S
    AIDS Behav; 2024 Mar; 28(3):907-911. PubMed ID: 37792228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment.
    Cole SW; Glick JL; Campoamor NB; Sanchez TH; Sarkar S; Vannappagari V; Rinehart A; Rawlings K; Sullivan PS; Bridges JFP
    BMJ Open; 2024 Apr; 14(4):e083837. PubMed ID: 38653510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
    McPherson TD; Sobieszczyk ME; Markowitz M
    Expert Opin Investig Drugs; 2018 Apr; 27(4):413-420. PubMed ID: 29633869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants.
    Johnson LF; Myer L; Jamieson L; Meyer-Rath G; Delany-Moretlwe S; Joseph Davey D
    AIDS; 2024 Mar; 38(4):589-594. PubMed ID: 38016171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.
    Zhao R; Fairley CK; Cook AR; Phanuphak N; He S; Tieosapjaroen W; Chow EPF; Phillips TR; Jin Tan RK; Wei Y; Shen M; Zhuang G; Ong JJ; Zhang L
    Lancet Glob Health; 2024 Feb; 12(2):e243-e256. PubMed ID: 38245115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?
    Levy ME; Agopian A; Magnus M; Rawls A; Opoku J; Kharfen M; Greenberg AE; Kuo I
    J Acquir Immune Defic Syndr; 2021 Mar; 86(3):e80-e82. PubMed ID: 33148996
    [No Abstract]   [Full Text] [Related]  

  • 18. A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention.
    Pilgrim NA; Evans TM; Czarnogorski M
    Health Promot Pract; 2022 Nov; 23(6):912-915. PubMed ID: 35713273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
    Tolley EE; Zangeneh SZ; Chau G; Eron J; Grinsztejn B; Humphries H; Liu A; Siegel M; Bertha M; Panchia R; Li S; Cottle L; Rinehart A; Margolis D; Jennings A; McCauley M; Landovitz RJ
    AIDS Behav; 2020 Sep; 24(9):2520-2531. PubMed ID: 32052214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP).
    Rael CT; Lopez-Ríos J; McKenna SA; Das D; Dolezal C; Abascal E; Carballo-Diéguez A; Schnall R; Hope TJ; Bauermeister J; Bockting W
    AIDS Behav; 2021 Dec; 25(12):4180-4192. PubMed ID: 34216284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.